The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Reverse causation in a cohort study of weight and outcome

This is a generated summary. It shows the 5 most-liked posts from a topic of 15, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
LV
l.vukovicTL2 Moderator23 Dec 2025#1

On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion.

Comparing SELECT (N Engl J Med, 2023) with FLOW (N Engl J Med, 2024) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

12 likes 7mo
D
DOdendaalTL3Regular25 Dec 2025#2

When you change your mind: if a reply convinces you that your criticism was not well-founded, say so plainly. The critique might still be real but smaller than you originally thought. That is not a failure — it is how discussion works.

16 likes 7mo
RI
r.ilungaTL2 Moderator26 Dec 2025#3

post #2 is right about the mechanism and I think understates the practical bit.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

32 likes 7mo
O
OTeixeiraTL3Regular28 Dec 2025#6

Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative statistical analysis might bias toward null.

23 likes 7mo
HN
h.nicolaidesTL3Regular1 Jan 2026#12
r.ilunga, post #3: post #2 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question. Sometimes that is what the sponsor wanted, sometimes the researchers did the best they could with constraints.

32 likes in reply to #3 7mo

Read the full topic (15 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…
LHCKSVCW+117 129 45k 5mo
Coming back to: A structured critique template this community uses
Posting this under the heading it deserves: A structured critique template this community uses Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med , 2022)…
SOFAKHASMY+63 69 17k 18h
A structured critique template this community uses
A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
ZOCEK 2 18k 1d
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim…
KBZOKOJMTV+55 61 60k 15mo
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support of a claim I do…
ASKHMIASNP+71 80 1.1k 14mo

Related topics — sharing the tags disputed, observational data, effect size

TopicParticipantsRepliesViewsActivity
The retatrutide phase 2 obesity paper, read closely
Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…
KTDEF 2 65k 10mo
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
AKACRIGKR+103 110 8.1k 2h
Sample size intuition for a personal experiment
On the subject in the title: Sample size intuition for a personal experiment Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is…
RKHECAHTT 4 62k 18mo
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
NNRNCIHBEK+4 8 142 6h
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…
SBKRSICPMN+27 31 1.2k 22h